This meta-analysis (Level 1b evidence) examined the efficacy and safety of two primary transurethral therapies used in the management of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH), enucleation (HoLEP – holmium laser enucleation of prostate, ThuLEP,...
A large proportion of urology involves the treatment of bladder outflow obstruction (BOO) in men. Yet BOO in men is very difficult to accurately quantify with the only regular non-invasive test being uroflowmetry. Pressure flow urodynamics may be considered the...
The market for bladder outflow obstruction surgery is currently wide open with new technologies such as Urolift® emerging. One of the key selling points of new technologies is the comparative safety and efficacy compared to traditional techniques such as transurethral...
This study is the first of its kind to report an association between men who have sex with men (MSM) and lower urinary tract symptoms (LUTS). Nine hundred and forty-nine consecutive individuals who presented to a uro-andrology clinic for complaints...
Randomised trials with use of sham is uncommon in the surgical literature, which makes this paper more interesting. Many different treatments are available for treating lower urinary tract symptoms / benign prostatic hyperplasia (LUTS / BPH). Prostatic artery embolisation (PAE)...
Whilst there is nothing unique in the individual chapters in this book it is rare for so many focused areas of interest to be integrated quite so well under one cover. The topics covered range from bladder emptying disorders to...
Benign prostatic hyperplasia (BPH) is characterised by stromal and epithelial prostatic cell hyperplasia. The enlarged prostate may be associated with voiding and storage lower urinary tract symptoms (LUTS). These have been predominantly attributed to bladder outlet obstruction (BOO), assumed to...
Case 1 Define the zonal anatomy of the prostate: A, B and C What is the significance of Zone A and Zone C? Clasify the types of lower urinary tract symptoms (LUTS) Which investigations should be routinely undertaken for a...
Mirabegron is a beta-3 agonist used in the treatment of overactive bladder (OAB). Trials have shown reduced side-effects but equal efficacy when compared to anticholinergics. The authors wished to examine patients’ persistence with treatment, in a non-trial setting, over a...
This prospective study on men undergoing transrectal ultrasonography (TRUS) biopsies was performed to evaluate the prevalence and to classify prostatic calcification (PCalc) on TRUS and correlate the findings with histology. Images of the prostate were saved at three defined regions:...
The menopause is a natural process of ageing when the ovaries completely stop producing reproductive hormones (oestrogen and other sex steroids), and there are no monthly periods for 12 consecutive months. It normally occurs between the ages of 45-55 years...
Introduction Benign prostatic hyperplasia (BPH), a common condition associated with ageing, affects 50% of those between the ages of 50 and 60 years, and as many as 90% of those older than 80 years. BPH is characterised by unregulated, benign...